YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer detection powered by DNA methylation and multi-biomarkers, next-generation precision diagnostics and stem cell therapy & exosome platforms focused on ophthalmology conditions. With 1,500+ visitors and 541 on-site surveys in 4 days, this significant event served as a critical gateway for YD Bio to connect with key stakeholders, explore new market opportunities globally, and reinforce its position as an innovator in the world’s healthcare landscape, providing an unparalleled platform to engage with